

"Express Mail" mailing label number EL 832895877 US

Date of Deposit 2-24-04

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Queen Thomas

Printed Name

Queen Thomas

Signature

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants	:	COHEN, Fredric Jay, et al.)
)
Serial No.	:	FILED CONCURRENTLY HEREWITH)
)
Filed	:	FILED CONCURRENTLY HEREWITH)
)
For	:	METHODS OF PREVENTING BREAST)
		CANCER)
)
Docket No.	:	X-11057C)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) for consideration by the Examiner.

As permitted by 37 C.F.R. §1.98(d), Applicants refer to application Serial Nos. 09/254,375, 09/368,688, and 09/931,159 filed March 29, 1999, August 5, 1999 and August 16, 2001, respectively for copies of the listed documents.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,



William R. Boudreaux
Attorney for Applicants
Registration No. 35,796
Phone: 317-276-0755

Eli Lilly and Company
Patent Division/WRB
P.O. Box 6288
Indianapolis, Indiana 46206-6288

24 February 2004

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-11057C	Serial No FILED CONCURRENTLY HEREWITH
	Applicants COHN, Fredric Jay, et al.	
	Filing Date FILED CONCURRENTLY HEREWITH	Group

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US 4,418,068	11/29/1983	Jones	
	AB	US 4,656,187	04/07/1987	Black, et al.	
	AC	US 5,478,847	12/26/1995	Draper	
	AD	US 5,604,248	02/18/1997	Bryant, et al.	
	AE	US 5,472,962	12/05/1995	Koizumi, et al.	
	AF	US 5,821,254	10/13/1998	Sporn, et al.	
	AG	US 5,075,321	12/24/1991	Schreiber	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)				
	BA	EP 680 758 A1	04/05/1995	EPO		
	BB	EP 652 004 A1	10/13/1994	EPO		
	BC	EP 674 903 A1	02/10/1995	EPO		
	BD	EP 0 839 532 A1	10/29/1997	EPO		
	BE	EP 0 659 419 A1	12/19/1994	EPO		
	BF	WO 96/22771	08/01/1996	PCT		
	BE	WO 97/35571	10/02/1997	PCT		

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-11057C	Serial No FILED CONCURRENTLY HEREWITH
	Applicants COHN, Fredric Jay, et al.	
	Filing Date FILED CONCURRENTLY HEREWITH	Group

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. I	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.		T ⁶
	CA	Jordan V. Craig: "Alternate Antiestrogens and Approaches to the Prevention of Breast Cancer"; Journal of Cellular Biochemistry, 58:S.22, pp. 51-57 (1995)		
	CB	Anzano, M. A., et al.: "Chemoprevention of Mammary Carcinogenesis in the Rat: Combined Use of Raloxifene and 9-Cis-Retinoic Acid"; Journal of the National Cancer Institute, 88:2, pp. 123-125 (1996)		
	CC	"First Phase III Results with Raloxifene": Database File 129, Dialog Information Services, 00540210, June 13, 1997		
	CD	"Market Analysis from Decision Resources: Breast Cancer"; Database File 187, Dialog Information Services, 1249, April 1, 1996		
	CE	"National Chemopreventive Agents in Experimental Mammary Carcinogenesis"; Anzano, Crisp Data Base National Institute of Health, CRISP-96-9057 (1995)		
	CF	Anzano: Caplus Abstract Accession Number 1996:122169 and J. National Cancer Institute (1996); 88(2), pp. 123-125		
	CG	Jordan: Biosis Abstract Accession Number 95:496471 and Breast Cancer Research and Treatment (1995); 36(3), pp. 267-285		
	CH	Jones: Caplus Abstract Accession Number 1984:448784 and J. Med. Chem. (1984); 27(8), pp. 1057-1066		
	CI	Clemens: Caplus Abstract Accession Number 1993:432846 and Life Science (1983); 32(25), pp. 2869-75		
	CJ	Lerner, L. J., et al.: "Development of Antiestrogens and Their Use in Breast Cancer: Eighth Cain Memorial Award Lecture"; Cancer Research, 50, pp. 4177-4189 (1990)		
	CK	Cummings, S. R., et al.: "The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women - Results from the MORE Randomized Trial"; JAMA, pp. 2189-2197 and p. 2124, Vol. 281, No. 23 (June 16, 1999)		
	CL	Cauley, J. A., et al.: "Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-year Results from the MORE Trial"; Breast Cancer Research and Treatment, 65: pp. 125-134 (2001)		
	CM	Buzdar, A. U., et al., "Phase II Evaluation of LY156758 in Metastatic Breast Cancer "; Oncology, 45: pp. 344-345 (1988)		
Examiner Signature		Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22313-1450.